Exposing the hidden disability through film.
Eighteen percent of all improperly used thrombolytic treatments in the emergency department occur in patients with migraine with aura.
New research may help doctors determine when (and when not) to test for antiglutamate decarboxylase antibodies in patients with neurological disorders and psychiatric symptoms.
A new study has found that patients with neuropsychiatric systemic lupus erythematosus have 3 times increased risk of death, and this risk increases to over 7 times higher in patients with focal CNS symptoms.
New research highlights prevention, diagnostic, and treatment advances for Alzheimer, autism, atherosclerosis, and more.
New technology may help patients and providers assess changes in severity of Parkinson disease symptoms more objectively.
Newly approved medications for various types of pain, generalized myasthenia gravis, and Parkinson disease will be fodder for discussion at AAN 2018. Here’s a brief overview of the therapies the FDA has approved within the past 6 months.
Findings from a new study indicate that compared with children who were not exposed to the drug, children with in utero exposure to sodium valproate have lower scores on national tests at age 7 years.
A study undertaken to evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine has led to an FDA extended indication.
Parkinson disease articles published in 2018 reveal deeper dives into factors that include the impact of sleep and fatigue on symptoms.